Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma

Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine

(2022) Valentin Van den bossche et al.   DRUG RESISTANCE UPDATES

Amino Acid Metabolism in Cancer Drug Resistance

(2022) Hee-Chan Yoo et al.   Cells

Deciphering molecular mechanisms underlying chemoresistance in relapsed AML patients: towards precision medicine overcoming drug resistance

(2021) May Levin et al.   Cancer Cell International

Amino Acid Transporters on the Guard of Cell Genome and Epigenome

(2021) Uğur Kahya et al.   Cancers

CD36-mediated ferroptosis dampens intratumoral CD8+ T cell effector function and impairs their antitumor ability

(2021) Xingzhe Ma et al.   Cell Metabolism

Integration of Metabolomics and Gene Expression Profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC-Diffuse Large B Cell Lymphoma

(2021) Fouad Choueiry et al.   Cancers

Pyruvate dehydrogenase kinase 4‐mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B‐cell lymphoma by affecting the expression of MS4A1/CD20

(2021) Duanfeng Jiang et al.   CANCER SCIENCE

GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer

(2021) Camilla Pecoraro et al.   DRUG RESISTANCE UPDATES

Hypoxia as a driver of resistance to immunotherapy

(2021) Joanna Kopecka et al.   DRUG RESISTANCE UPDATES

Anticancer drug resistance: An update and perspective

(2021) Ruth Nussinov et al.   DRUG RESISTANCE UPDATES

Impact of cancer metabolism on therapy resistance – Clinical implications

(2021) Ana Cristina Gonçalves et al.   DRUG RESISTANCE UPDATES

Cooperative miRNA-dependent PTEN regulation drives resistance to BTK inhibition in B-cell lymphoid malignancies

(2021) Isha Kapoor et al.   Cell Death & Disease

Regulation of B-cell function by NF-kappaB c-Rel in health and disease

(2020) Shrikanth C. Basavarajappa et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Lipid rafts as signaling hubs in cancer cell survival/death and invasion: implications in tumor progression and therapy

(2020) Faustino Mollinedo et al.   JOURNAL OF LIPID RESEARCH

Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T cell dysfunction

(2020) Nathan Singh et al.   Cancer Discovery

Fatty acid synthase and adenosine monophosphate-activated protein kinase regulate cell survival and drug sensitivity in diffuse large B-cell lymphoma

(2020) Grace K. Gifford et al.   LEUKEMIA & LYMPHOMA

Dihydroartemisinin Inhibits the Proliferation of Leukemia Cells K562 by Suppressing PKM2 and GLUT1 Mediated Aerobic Glycolysis

(2020) Peng Gao et al.   Drug Design Development and Therapy

Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas

(2020) Bhawana George et al.   Cancers

Metabolic Reprogramming and Epithelial-Mesenchymal Plasticity: Opportunities and Challenges for Cancer Therapy

(2020) Nai-Yun Sun et al.   Frontiers in Oncology

Function and regulation of lipid signaling in lymphomagenesis: a novel target in cancer research and therapy

(2020) Wei Guo et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Inhibitors of lipogenic enzymes as a potential therapy against cancer

(2020) Nicolás Montesdeoca et al.   FASEB JOURNAL

Expression of hypoxia‐inducible factor 1α, glucose transporter 1, and hexokinase 2 in primary central nervous system lymphoma and the correlation with the biological behaviors

(2020) Na Shen et al.   Brain and Behavior

Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma

(2020) Wei Sang et al.   Cancer Medicine

Molecular Mechanisms of Adipogenesis: The Anti-adipogenic Role of AMP-Activated Protein Kinase

(2020) Bilal Ahmad et al.   Frontiers in Molecular Biosciences

Metformin sensitizes therapeutic agents and improves outcome in pre-clinical and clinical diffuse large B-cell lymphoma

(2020) Anil R. Singh et al.   Cancer & Metabolism

Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance

(2020) Nir Shahar et al.   DRUG RESISTANCE UPDATES

Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker

(2020) Zhengyi Wang et al.   Cancer Medicine

Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification

(2020) Bowen Li et al.   DRUG RESISTANCE UPDATES

Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance

(2020) Nuray Erin et al.   DRUG RESISTANCE UPDATES

Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies

(2020) Elisabeth Pérez-Ruiz et al.   DRUG RESISTANCE UPDATES

New agents and regimens for diffuse large B cell lymphoma

(2020) Liang Wang et al.   Journal of Hematology & Oncology

SIRT3, a metabolic target linked to ataxia-telangiectasia mutated (ATM) gene deficiency in diffuse large B-cell lymphoma

(2020) Kavita Bhalla et al.   Scientific Reports

Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy Resistance

(2020) Madeleine R. Berendsen et al.   Cancers

Fluorescent Imaging for Cysteine Detection In Vivo with High Selectivity

(2019) Zhuwen Duan et al.   ChemistryOpen

p53 Promotes Cancer Cell Adaptation to Glutamine Deprivation by Upregulating Slc7a3 to Increase Arginine Uptake

(2019) Xazmin H. Lowman et al.   Cell Reports

Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors

(2019) Ariella B. Hanker et al.   Cancer Discovery

Chewing the Fat: The Conserved Ability of DNA Viruses to Hijack Cellular Lipid Metabolism

(2019) Philip Lange et al.   Viruses-Basel

AMP-activated protein kinase: the current landscape for drug development

(2019) Gregory R. Steinberg et al.   NATURE REVIEWS DRUG DISCOVERY

Germinal center‐derived lymphomas: The darkest side of humoral immunity

(2019) Coraline Mlynarczyk et al.   IMMUNOLOGICAL REVIEWS

YY1 regulates cancer cell immune resistance by modulating PD-L1 expression

(2019) Emily Hays et al.   DRUG RESISTANCE UPDATES

Surmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine

(2019) May Levin et al.   Cell Death & Disease

Deciphering the Elevated Lipid via CD36 in Mantle Cell Lymphoma with Bortezomib Resistance Using Synchrotron-Based Fourier Transform Infrared Spectroscopy of Single Cells

(2019) Sudjit Luanpitpong et al.   Cancers

Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis

(2019) Meng Li et al.   CANCER CELL

Exosomes and their role in tumorigenesis and anticancer drug resistance

(2019) Neta Milman et al.   DRUG RESISTANCE UPDATES

Immune checkpoint inhibitor combinations: Current efforts and important aspects for success

(2019) Edo Kon et al.   DRUG RESISTANCE UPDATES

HSP90 Molecular Chaperones, Metabolic Rewiring, and Epigenetics: Impact on Tumor Progression and Perspective for Anticancer Therapy

(2019) Valentina Condelli et al.   Cells

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies

(2019) Romain Guièze et al.   CANCER CELL

The multi-factorial nature of clinical multidrug resistance in cancer

(2019) Yehuda G. Assaraf et al.   DRUG RESISTANCE UPDATES

Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer

(2019) Alessandro Leonetti et al.   DRUG RESISTANCE UPDATES

Tumor Metabolism as a Regulator of Tumor–Host Interactions in the B-Cell Lymphoma Microenvironment—Fueling Progression and Novel Brakes for Therapy

(2019) Anna C. Beielstein et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma

(2019) Pavel Klener   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma

(2019) Jeremy S. Abramson   TRANSFUSION MEDICINE REVIEWS

Leveraging insights into cancer metabolism—a symposium report

(2019) Jennifer Cable et al.   Annals of the New York Academy of Sciences

Towards the overcoming of anticancer drug resistance mediated by p53 mutations

(2019) Xin Cao et al.   DRUG RESISTANCE UPDATES

Targeting cancer's metabolic co-dependencies: A landscape shaped by genotype and tissue context

(2018) Junfeng Bi et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas

(2018) Lan V. Pham et al.   CLINICAL CANCER RESEARCH

How the Warburg effect supports aggressiveness and drug resistance of cancer cells?

(2018) Philippe Icard et al.   DRUG RESISTANCE UPDATES

How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance

(2018) Thorsten Stiewe et al.   DRUG RESISTANCE UPDATES

Redundant angiogenic signaling and tumor drug resistance

(2018) Rajesh N. Gacche et al.   DRUG RESISTANCE UPDATES

Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia

(2018) Mark A. Gregory et al.   EXPERIMENTAL HEMATOLOGY

CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis

(2018) Lei Zhao et al.   JOURNAL OF HEPATOLOGY

Diffuse large B-cell lymphoma

(2018) Shaoying Li et al.   PATHOLOGY

Skp2-dependent reactivation of AKT drives resistance to PI3K inhibitors

(2018) Emilie Clement et al.   Science Signaling

Fatty Acid Synthase induced S6Kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in DLBCL

(2018) Bandish Kapadia et al.   Nature Communications

CXCR4 can induce PI3Kδ inhibitor resistance in ABC DLBCL

(2018) Joo Hyun Kim et al.   Blood Cancer Journal

Role of hypoxia in Diffuse Large B-cell Lymphoma: Metabolic repression and selective translation of HK2 facilitates development of DLBCL

(2018) Kavita Bhalla et al.   Scientific Reports

Skp2-dependent reactivation of AKT drives resistance to PI3K inhibitors

(2018) Emilie Clement et al.   Science Signaling

Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma

(2018) Xiaoxiao Wang et al.   NEOPLASIA

Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway

(2018) Benet Pera et al.   EBioMedicine

A Role for p53 in the Adaptation to Glutamine Starvation through the Expression of SLC1A3

(2018) Mylène Tajan et al.   Cell Metabolism

Precision medicine in head and neck cancer

(2018) Orit Kaidar-Person et al.   DRUG RESISTANCE UPDATES

Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets

(2018) Vera Miranda-Gonçalves et al.   Frontiers in Genetics

Metabolic Reprogramming of Non-Hodgkin's B-Cell Lymphomas and Potential Therapeutic Strategies

(2018) Jean-Ehrland Ricci et al.   Frontiers in Oncology

Glutaminolysis Mediated by MALT1 Protease Activity Facilitates PD-L1 Expression on ABC-DLBCL Cells and Contributes to Their Immune Evasion

(2018) Xichun Xia et al.   Frontiers in Oncology

MYC protein dysregulation is driven by BCR-PI3K signalling in diffuse large B-cell lymphoma

(2017) Wei-Ge Wang et al.   HISTOPATHOLOGY

Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial

(2017) Andrew D Zelenetz et al.   LANCET ONCOLOGY

Pathways and mechanisms of venetoclax resistance

(2017) Prithviraj Bose et al.   LEUKEMIA & LYMPHOMA

Rational Targeting of Cellular Cholesterol in Diffuse Large B-Cell Lymphoma (DLBCL) Enabled by Functional Lipoprotein Nanoparticles: A Therapeutic Strategy Dependent on Cell of Origin

(2017) Jonathan S. Rink et al.   MOLECULAR PHARMACEUTICS

AMPK: guardian of metabolism and mitochondrial homeostasis

(2017) Sébastien Herzig et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Mitochondrial ribosomes in cancer

(2017) Hyun-Jung Kim et al.   SEMINARS IN CANCER BIOLOGY

Mitochondrial and glycolytic metabolic compartmentalization in diffuse large B-cell lymphoma

(2017) Mahasweta Gooptu et al.   SEMINARS IN ONCOLOGY

MYC is a positive regulator of choline metabolism and impedes mitophagy-dependent necroptosis in diffuse large B-cell lymphoma

(2017) J Xiong et al.   Blood Cancer Journal

Precision Nutrition for Targeting Lipid Metabolism in Colorectal Cancer

(2017) Cristina Aguirre-Portolés et al.   Nutrients

Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity

(2017) Nicola J. Curtis et al.   Oncotarget

ASCT2 (SLC1A5)-Deficient Mice Have Normal B-Cell Development, Proliferation, and Antibody Production

(2017) Etienne Masle-Farquhar et al.   Frontiers in Immunology

Teaching the basics of cancer metabolism: Developing antitumor strategies by exploiting the differences between normal and cancer cell metabolism

(2017) Balaraman Kalyanaraman   Redox Biology

TP53 dysfunction in diffuse large B-cell lymphoma

(2016) Ting-Xun Lu et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

The reduced concentration of citrate in cancer cells: An indicator of cancer aggressiveness and a possible therapeutic target

(2016) Icard Philippe et al.   DRUG RESISTANCE UPDATES

Could drugs inhibiting the mevalonate pathway also target cancer stem cells?

(2016) Wirginia Likus et al.   DRUG RESISTANCE UPDATES

Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics

(2016) Ruud H. Wijdeven et al.   DRUG RESISTANCE UPDATES

Y-box-binding protein-1 (YB-1) promotes cell proliferation, adhesion and drug resistance in diffuse large B-cell lymphoma

(2016) Xiaobing Miao et al.   EXPERIMENTAL CELL RESEARCH

Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses

(2016) Prithviraj Bose et al.   Expert Opinion on Drug Metabolism & Toxicology

LncRNA NBR2 engages a metabolic checkpoint by regulating AMPK under energy stress

(2016) Xiaowen Liu et al.   NATURE CELL BIOLOGY

Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction

(2016) T Q Tran et al.   ONCOGENE

Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma

(2016) Ha Young Park et al.   Oncotarget

TRAF3 deficiency promotes metabolic reprogramming in B cells

(2016) Nurbek Mambetsariev et al.   Scientific Reports

Lipid metabolic reprogramming in cancer cells

(2016) S Beloribi-Djefaflia et al.   Oncogenesis

IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias

(2016) Samuel Gusscott et al.   PLoS One

Drugging PI3K in cancer: refining targets and therapeutic strategies

(2015) Timothy A Yap et al.   CURRENT OPINION IN PHARMACOLOGY

Clinicopathological implications of nuclear factor κB signal pathway activation in diffuse large B-cell lymphoma

(2015) Qian Zhao et al.   HUMAN PATHOLOGY

Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment

(2015) Kazuhiro Tanaka et al.   JOURNAL OF CLINICAL INVESTIGATION

The anti-tumor efficacy of 2-deoxyglucose and D-allose are enhanced with p38 inhibition in pancreatic and ovarian cell lines

(2015) Scott W Malm et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

CD79B limits response of diffuse large B cell lymphoma to ibrutinib

(2015) Joo Hyun Kim et al.   LEUKEMIA & LYMPHOMA

Amino acid management in cancer

(2015) Zhi-Yang Tsun et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma

(2015) Ling Li et al.   Oncotarget

Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2

(2015) Yan Luo et al.   Oncotarget

Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/ mTOR signaling

(2015) Laura Mediani et al.   Oncotarget

Pharmacologically blocking p53-dependent apoptosis protects intestinal stem cells and mice from radiation

(2015) Xinwei Wang et al.   Scientific Reports

Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma

(2014) James S. Blachly et al.   BRITISH JOURNAL OF HAEMATOLOGY

Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin

(2014) S. Dalva-Aydemir et al.   CLINICAL CANCER RESEARCH

Glycolytic inhibitor 2-deoxy-d-glucose suppresses cell proliferation and enhances methylprednisolone sensitivity in non-Hodgkin lymphoma cells through down-regulation of HIF-1α and c-MYC

(2014) Yu-Yang Pang et al.   LEUKEMIA & LYMPHOMA

Investigating and targeting chronic lymphocytic leukemia metabolism with the human immunodeficiency virus protease inhibitor ritonavir and metformin

(2014) Kehinde U. A. Adekola et al.   LEUKEMIA & LYMPHOMA

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

(2014) Richard R. Furman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of LDH-A and Glutaminase Inhibition In Vivo by Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopy of Tumors

(2013) P. Dutta et al.   CANCER RESEARCH

Blocking Lactate Export by Inhibiting the Myc Target MCT1 Disables Glycolysis and Glutathione Synthesis

(2013) J. R. Doherty et al.   CANCER RESEARCH

An Essential Requirement for the SCAP/SREBP Signaling Axis to Protect Cancer Cells from Lipotoxicity

(2013) K. J. Williams et al.   CANCER RESEARCH

Molecular Pathways: Targeting MYC-induced Metabolic Reprogramming and Oncogenic Stress in Cancer

(2013) B. Li et al.   CLINICAL CANCER RESEARCH

AMPK-Dependent Degradation of TXNIP upon Energy Stress Leads to Enhanced Glucose Uptake via GLUT1

(2013) Ning Wu et al.   MOLECULAR CELL

Diffuse large B-cell lymphoma—treatment approaches in the molecular era

(2013) Mark Roschewski et al.   Nature Reviews Clinical Oncology

Stimulation of de Novo Pyrimidine Synthesis by Growth Signaling Through mTOR and S6K1

(2013) I. Ben-Sahra et al.   SCIENCE

Targeting cellular metabolism to improve cancer therapeutics

(2013) Y Zhao et al.   Cell Death & Disease

MYC on the Path to Cancer

(2012) Chi V. Dang   CELL

Glucose-Independent Glutamine Metabolism via TCA Cycling for Proliferation and Survival in B Cells

(2012) Anne Le et al.   Cell Metabolism

Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance

(2012) Nitzan Gonen et al.   DRUG RESISTANCE UPDATES

Cancer cell growth and survival as a system-level property sustained by enhanced glycolysis and mitochondrial metabolic remodeling

(2012) Lilia Alberghina et al.   Frontiers in Physiology

IKK  and NF- B Transcription Govern Lymphoma Cell Survival through AKT-Induced Plasma Membrane Trafficking of GLUT1

(2011) T. G. Sommermann et al.   CANCER RESEARCH

Hypoxia-mediated drug resistance: Novel insights on the functional interaction of HIFs and cell death pathways

(2011) Nadine Rohwer et al.   DRUG RESISTANCE UPDATES

Metabolic regulation by p53

(2011) Oliver D. K. Maddocks et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Resveratrol Suppresses Constitutive Activation of AKT via Generation of ROS and Induces Apoptosis in Diffuse Large B Cell Lymphoma Cell Lines

(2011) Azhar R. Hussain et al.   PLoS One

PI3K/Akt signaling requires spatial compartmentalization in plasma membrane microdomains

(2011) X. Gao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies

(2010) Saroj P. Mathupala et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS

Glutaminolysis: Supplying carbon or nitrogen or both for cancer cells?

(2010) Chi V. Dang   CELL CYCLE

Inhibition of Fatty Acid Synthase Suppresses c-Met Receptor Kinase and Induces Apoptosis in Diffuse Large B-Cell Lymphoma

(2010) S. Uddin et al.   MOLECULAR CANCER THERAPEUTICS

Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1

(2010) Katrin Düvel et al.   MOLECULAR CELL

Glutamine addiction: a new therapeutic target in cancer

(2010) David R. Wise et al.   TRENDS IN BIOCHEMICAL SCIENCES

De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy

(2009) T Mashima et al.   BRITISH JOURNAL OF CANCER

MYC-Induced Cancer Cell Energy Metabolism and Therapeutic Opportunities

(2009) C. V. Dang et al.   CLINICAL CANCER RESEARCH

HIF-1: upstream and downstream of cancer metabolism

(2009) Gregg L Semenza   CURRENT OPINION IN GENETICS & DEVELOPMENT

Glycolytic Flux Signals to mTOR through Glyceraldehyde-3-Phosphate Dehydrogenase-Mediated Regulation of Rheb

(2009) M. N. Lee et al.   MOLECULAR AND CELLULAR BIOLOGY

Fatty Acid Synthase Gene Is Up-regulated by Hypoxia via Activation of Akt and Sterol Regulatory Element Binding Protein-1

(2008) E. Furuta et al.   CANCER RESEARCH

The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation

(2008) Ralph J. DeBerardinis et al.   Cell Metabolism

Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation

(2008) Rémi Lasserre et al.   Nature Chemical Biology

Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction

(2008) D. R. Wise et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

(2008) G. Lenz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA